BMRN Stock — Biomarin Pharmaceutical Inc

Up next

Next earnings call

Nov 3, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

+2.9%

Trailing year

Short interest

5.2%

Latest settlement · 5.5 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. BioMarin reported Q2 2026 revenue up 20% year-over-year to $990 million and raised full-year 2026 guidance for total revenues, Voxzogo, and non-GAAP diluted EPS, driven by strong demand and initial contributions from the recently closed Amicus acquisition (Galafold and Pombiliti+Opfolda), while integration-related costs and higher interest expense pressured GAAP and non-GAAP earnings.

Bullish

+ Q2 total revenue grew 20% Y/Y to $990 million with raised full-year 2026 guidance
+ Raised full-year 2026 Voxzogo revenue guidance to at least $1 billion on 14% Q2 Voxzogo growth
+ Galafold and Pombiliti+Opfolda peak revenue potential of $2.6 billion with ~$220M synergies fully realized in 2028
+ Submitted Voxzogo sNDA for hypochondroplasia with potential 2027 launch
+ Deleverage target pulled forward ~1 year to below 2.5x gross leverage by mid-2027

Bearish

− GAAP net income fell 81% Y/Y to $45M due to Amicus acquisition costs and higher interest expense
− ~$200M annualized acquisition-related interest expense expected to weigh on near-term earnings
− Discontinued BMN 401 development after failing an ENPP1 deficiency co-primary endpoint

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −3%

below

Price vs 50-day avg −11%

below

RSI (14) 27

oversold

MACD trend Negative

52-week position 37%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −14%

trailing

6-month return +4%

trailing

YTD return −4%

this year

Relative strength −8%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $64 › 200d $59 — 50d above 200d

Institutional flow Accumulating

5 of 568 funds reported for Sep 30 · net +31.9K sh shares · +1 new

Insider flow Distributing

Net -$1.2M over 90 days · 100% sells

Short interest Rising

5.21% of float · ▲ +2.0% MoM · 5.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

568 holders — mid 3-yr range

Squeeze score 60

elevated · 0–100

Fundamentals

Strong

Revenue growth +18%

Y/Y

EPS growth −19%

Y/Y

Free cash flow $725.0M

Valuation P/E 153.5

rich

Balance sheet $714.5M

net cash

Quant / Vol

risk profile

Moderate

Volatility 35%

annualized · 1-yr

Max drawdown −22%

past year

ATR 2.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 2 of last 2

Latest guidance · from the 8-K filed Aug 6, 2026

mid-2030s

GALAFOLD peak revenue $1.4B

mid-to-late-2030s

POMBILITI + OPFOLDA peak revenue $1.2B

fully realized in 2028

GAAP cost reductions (synergies) $280M

Non-GAAP cost reductions (synergies) $220M

by 2030

Non-GAAP Operating Margin (GALAFOLD and POMBILITI + OPFOLDA comb at least 60%

Guided vs delivered · last 2 settled

GAAP Diluted EPS Full-year 2023

guided $0.85 – $1.05

guided $0.85 – $1.05 $0.87 In line

Full-year 2020 revenues full year 2020

guided $1.85B – $1.95B

guided $1.85B – $1.95B $1.86B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

2 · 5 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−3% Neutral

Price vs 50-day avg

−11% Bearish

RSI (14)

27 Neutral

MACD trend

Negative Bearish

52-week position

37% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $64 › 200d $59 — 50d above 200d

Institutional flow Accumulating

5 of 568 funds reported for Sep 30 · net +31.9K sh shares · +1 new

Insider flow Distributing

Net -$1.2M over 90 days · 100% sells

Short interest Rising

5.21% of float · ▲ +2.0% MoM · 5.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

568 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $50 Now $57 · 37% Range high $70

vs 200-day avg -3% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Non-GAAP Diluted EPS non-GAAP	$1.96	Six Months Ended June 30, 2026	-23.7%

Non-GAAP Income from Operations non-GAAP	$545M	Six Months Ended June 30, 2026	-8.6%

Non-GAAP Operating Margin % non-GAAP	36.4%	Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
BMRN Biomarin Pharmaceutical Inc this stock	$11.59B	-3.8%	+17.6%	153.5	5.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

569

% held: 101.4%
Reported: 5 of 568
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

530

View

Short & Settlement

Short Interest Rising

Shares short

10.1M

Days to cover: 5.5d
Change: +198.1K sh

View

Short Volume

Short vol %

57%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

47.8K

Value: $3.1M
As of: Sep 2, 2026

View

Off-Exchange

Off-exchange %

43.6%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$1.2M

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Mar 6, 2023

View

Financials

Revenue (FY)

$3.2B

Net income (FY): $348.9M
EPS diluted: $1.80

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 30, 2026
This year: 25

View

Proposed Sales

Value

$1.2M

Shares: 17.6K
Filed: Sep 2, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 9, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
BMRN	-5.1%	-13.9%	+4.2%	-4.7%	-3.8%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-4.9%	-13.5%	-8.0%	-5.6%	-16.7%

BMRN · Biomarin Pharmaceutical Inc

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance